XASX
HYD
Market cap610kUSD
Oct 09, Last price
0.00AUD
1D
0.00%
1Q
-25.00%
Jan 2017
-99.41%
IPO
-99.93%
Name
Hydrix Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hydrix Limited, together with its subsidiaries, operates as a product design and engineering company in Australia, Europe, North America, Singapore, and internationally. It operates in three segments: Hydrix Services, Hydrix Medical, and Hydrix Ventures. The company offers product design and development consulting services comprising systems engineering, software, electronics, mechanical, human factors, and industrial design services; and product consulting services consisting of engineering design, development, prototyping, manufacturer management, and certification process management services. It also distributes cardiovascular products comprising Guardian, a heart attack warning system; and Implicity, a cloud-based AI-driven remote cardiac patient monitoring and data management software. In addition, the company invests in early stage medical technology (medtech) companies. It serves the cardiovascular, medtech, defence, and industrial industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is based in Mulgrave, Australia.
Key people
Gareth Evans
Chief Financial Officer · since 2025
Gavin Coote
Executive Chairman of the Board · since 2020
Company Secretary · since 2016
Julie King
Non-Executive Director · since 2017
Paul Lewis
Non-Executive Director · since 2021
Paul Wright
Non-Executive Independent Director · since 2018
Headquarters & legal address
30-32 COMPARK CIRCUIT
MULGRAVE, VIC 3170
AU
MULGRAVE, VIC 3170
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||